Prof Andreas Suhrbier is Group Leader of the Inflammation Biology Group at the QIMR Berghofer Medical Research Institute, Brisbane, Australia, and a Principal Research Fellow with the National Health & Medical Research Council (Australia). He has over 140 publications in the fields of virology, immunology and cancer therapeutics. He is an inventor on 17 patents, 12 have been commercialised, 7 cover products in human clinical trials, 5 cover ingenol mebutate/Picato, a topical anti-cancer agent recently approved in the USA, EU and Australia. He is, and has been a consultant for, and conducted collaborative R&D with, a number of local and international biotech and pharma companies. Currently funded research projects include chikungunya virus arthritis and the role of SerpinB2 in inflammation. Publications: http://scholar.google.com.au/citations?hl=en&user=KxKWgxwAAAAJ&view_op=list_works&sortby=pubdate Home page: www.qimrberghofer.edu.au/page/Lab/Inflammation_Biology/